Subject to change.
Subject to change.
Paul Gerrard is a physician leader specializing in market access for novel healthcare technologies. Dr. Gerrard serves as the Head of Global Market Access and Reimbursement at PathAI, a leader in AI-powered precision pathology, and as a co-chair of the DPA’s Reimbursement Task Force. Dr. Gerrard is known for his systematic approach to market access, aligning a company’s goals with the requirements of health policymakers and payers, so that healthcare innovations reach patients.
Digital pathology adoption and AI image analysis show significant potential, but return on investment (ROI) remains a challenge. The lack of reimbursement for FDA-cleared digital pathology (DP) solutions is a major barrier to widespread adoption. The DPA Reimbursement Task Force has a mission to 'To define and shape the pathway to reimbursement for digital pathology solutions enabling broad market access and delivery of value to patients and stakeholders. This session will provide an update on the key work of the DPA Reimbursement Task Force and provide a detailed look into the framework for DP AI reimbursement that the task force is pursuing. In addition, we will hear from experts on key changes to the reimbursement landscape in the US and important trends that are shaping how these solutions are being brought to the market.
Learning Objectives: